Core Viewpoint - The Department of Justice is investigating UnitedHealth for allegedly encouraging staff to make specific diagnoses that would lead to higher Medicare payments, particularly under the Medicare Advantage program [1][6]. Investigation Details - The investigation involves inquiries from the Justice Department, FBI, and Health and Human Services regarding patient testing, diagnostic procedures, and the process of sending nurses to patients' homes [2]. - Former employees reported that investigators asked about training related to making diagnoses and the methods used to contact patients for testing [4][8]. Company Response - UnitedHealth maintains that it supports the integrity of its Medicare Advantage business and welcomes regular reviews of its practices [3]. - The company criticized the Wall Street Journal for what it perceives as a biased narrative against Medicare Advantage, claiming reliance on incomplete data [3][4]. Diagnostic Practices - Former doctors indicated that the focus was on coding practices, specifically how diagnosis codes are submitted to Medicare for payments [5]. - Investigators inquired about bonuses for doctors reviewing potential diagnoses suggested by UnitedHealth [7]. Software and Tools - The investigation also looked into the "diagnosis cart" feature of UnitedHealth's software, which suggests potential medical conditions to nurses [11]. - UnitedHealth argues that its diagnostic practices are aimed at early disease detection and plans to implement independent third-party oversight for these practices [8]. Previous Investigations - A separate decade-long effort by the Justice Department to recover alleged Medicare overpayments from UnitedHealth was unsuccessful [10].

Core Viewpoint - UnitedHealth Group, Inc. is facing increased legal challenges as shareholders file multiple lawsuits related to a federal investigation into the company's Medicare billing practices, which were highlighted in a Wall Street Journal report [1][3]. Summary by Sections Legal Actions - Steve Silverman, a long-time shareholder, has filed a derivative lawsuit in federal court, claiming that UnitedHealth's leadership has harmed the company through questionable billing practices [2]. - The lawsuit accuses CEO Stephen Hemsley, former CEO Andrew Witty, and board members of engaging in practices that led to inflated reimbursements, significantly impacting the company's financial results and stock price [3][4]. - Other shareholders have also filed lawsuits, with one alleging that Hemsley and Witty profited from stock sales before the DOJ investigation became public [5][6]. Financial Impact - The lawsuits focus on the profitability of UnitedHealth's Medicare business, which has drawn negative attention and affected its stock price [6]. - Allegations include that the company repurchased $7.3 billion in stock at inflated prices while executives profited from share sales during the undisclosed DOJ investigation [9]. Company Challenges - UnitedHealth is currently navigating a series of challenges, including ongoing lawsuits, a DOJ investigation, regulatory changes, and leadership changes following the resignation of CEO Andrew Witty [7][10]. - The company's stock has seen a significant decline, falling over 40% year-to-date, with shares trading at $302.10 at the time of the report [11].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization for the second half of the year, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - The company reported Q3 2024 financial results on October 17, 2024, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. EPS guidance for 2024 was lowered from $37.20 to $33.00, or 11.3% [5]. - Following the Q3 results, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. stock purchase is from April 18, 2024, to October 16, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by July 11, 2025, to serve as lead plaintiff [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its financial guidance [4] - It is claimed that the acuity and utilization of Elevance's Medicaid members increased significantly, contrary to the company's assurances to investors [4] - The misrepresentation of the Medicaid expenses and the impact on financial guidance led to investor damages when the true situation was revealed [4]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023 [3]. Group 3: Allegations of Misrepresentation - Elevance claimed to be closely monitoring cost trends related to the Medicaid redetermination process and asserted that negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Price Impact - On July 17, 2024, Elevance announced an expectation of increased Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - Following the Q3 2024 financial results announcement on October 17, 2024, which revealed a miss in EPS expectations by $1.33 (13.7%) due to elevated medical costs, the stock price fell by $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Core Insights - A federal court ruling has increased Alignment Healthcare's Arizona HMO 2025 star rating from 3.5 to 4 stars, resulting in 100% of its Medicare Advantage members being enrolled in plans rated 4 stars or higher [1][2] Company Overview - Alignment Healthcare serves approximately 217,500 Medicare beneficiaries across five states: Arizona, California, Nevada, North Carolina, and Texas [3] - The company has received accolades such as a 4.9 out of 5-star Google rating and being named a Newsweek World's Most Trustworthy Company 2024 [3] Quality of Care - The Star Ratings program evaluates Medicare Advantage plans annually on a 5-star scale based on various quality measures, including preventive care, chronic disease management, customer service, and member satisfaction [2] - Plans that achieve 4 stars or higher qualify for bonus payments from CMS, which are reinvested to enhance member benefits and services [2] Strategic Positioning - The court's decision affirms the quality of care provided by Alignment Healthcare and enhances the confidence of Arizona members in their plan's quality [2] - The company aims to deliver more value to its members and provider partners, reinforcing its commitment to high-quality Medicare Advantage services [3] Mission and Values - Alignment Health focuses on empowering seniors to age well and live vibrant lives, emphasizing high-quality, low-cost care for its Medicare Advantage members [4] - The company partners with trusted local providers to deliver coordinated care, supported by a customized care model and a 24/7 concierge care team [4]

Core Insights - The Cigna Group Foundation has announced a new round of grants totaling $9 million over three years, focusing on improving the mental health of military veterans by addressing social determinants of health, particularly housing stability [1][6][8] Grant Program Details - The 2025 grant application is open for eligible organizations in select states, closing on August 7, 2025 [2] - The foundation prioritizes grants in regions with high social determinant of health risks, including Arizona, Connecticut, Florida, Georgia, Illinois, Missouri, New Jersey, Pennsylvania, Tennessee, and Texas [3][6] - Goals of the grant program include increasing permanent housing for veterans, improving housing affordability through rental or mortgage assistance, and enhancing wraparound services for veterans transitioning from shelters [3][6] Veteran Mental Health Context - Military veterans face a higher risk of homelessness, with approximately 40,000 veterans without shelter on any given night, and a 7% increase in homelessness among veterans reported from 2022 to 2023 [4][6] Previous Funding Impact - In 2024, the first year of the grant program, $3 million was distributed to 23 organizations to support local veterans, focusing on stability and mental health [5][6] - Examples of funded initiatives include the Veterans Rapid Rehousing Program in Texas and financial assistance for veteran homeowners facing foreclosure in Tennessee [7] Broader Philanthropic Commitment - The Cigna Group Foundation has committed over $27 million in grants over three years to address youth and veteran mental health and reduce barriers to health equity [8]

Core Viewpoint - Centene Corporation is facing potential legal claims regarding violations of federal securities laws and unlawful business practices following a significant drop in stock price after withdrawing its 2025 earnings guidance [1][2]. Group 1: Company Performance - On July 2, 2025, Centene's stock price fell over 39.5% during intraday trading after the company announced the withdrawal of its 2025 earnings guidance due to higher-than-expected costs related to Medicaid enrollees and underperformance in its Affordable Care Act plans [2]. - The company indicated that its Medicaid business has seen an increase in medical cost trends in areas such as behavioral health, home health, and high-cost drugs [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Centene on behalf of its stockholders, focusing on whether the company has violated federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses or have information regarding these claims [3].

Core Viewpoint - Elevance Health, Inc. is facing a class action lawsuit from investors who purchased securities during the specified Class Period, alleging misleading statements regarding Medicaid cost trends and financial guidance [1][3]. Group 1: Class Action Details - The class action represents investors who bought Elevance securities between April 18, 2024, and October 16, 2024, with a deadline of July 11, 2025, for filing a lead plaintiff motion [1]. - Investors are encouraged to contact the Portnoy Law Firm for a complimentary case evaluation and to discuss their legal rights [2]. Group 2: Allegations Against Elevance - The complaint alleges that Elevance's management misled investors about the Medicaid redetermination process, claiming they were monitoring cost trends and that premium rates were adequate [3]. - It is claimed that the redetermination process resulted in a higher-risk Medicaid population, which was not accurately reflected in Elevance's financial projections or rate negotiations for 2024 [3].